Long term efficacy and safety of patients with Ankylosing spondylitis treated with etanercept for 5 years: Analysis of different types of response

被引：0
|
作者：
Baraliakos, Xenofon [1 ]
Listing, J. [2 ]
Fritz, C. [2 ]
Song, In-Ho [3 ]
Haibel, H. [3 ]
Heldmann, F. [1 ]
Rudwaleit, M. [3 ]
Sieper, J. [3 ]
Braun, Juergen [1 ]
机构：
[1] Rheumazentrum Ruhrgebiet, Herne, Germany
[2] German Rheumatism Res Ctr, Berlin, Germany
[3] Charite, Berlin, Germany
来源：
ARTHRITIS AND RHEUMATISM | 2008年 / 58卷 / 09期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：S357 / S357
页数：1
相关论文
共 50 条
  • [11] Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis
    Martin-Mola, E.
    Sieper, J.
    Leirisalo-Repo, M.
    Dijkmans, B. A. C.
    Vlahos, B.
    Pedersen, R.
    Koenig, A. S.
    Freundlich, B.
    CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2010, 28 (02) : 238 - 245
  • [12] Safety and efficacy of etanercept therapy in ankylosing spondylitis patients undergoing phacoemulsification surgery
    Kemeny-Beke, Adam
    Szekanecz, Zoltan
    Szanto, Sandor
    Bodnar, Nora
    Modis, Laszlo, Jr.
    Gesztelyi, Rudolf
    Zsuga, Judit
    Szodoray, Peter
    Berta, Andras
    RHEUMATOLOGY, 2010, 49 (11) : 2220 - 2221
  • [13] Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
    Davis, J. C.
    van der Heijde, D.
    Braun, D.
    Dougados, M.
    Clegg, D. O.
    Kivits, A.
    Fleischmann, R.
    Inmann, R.
    Ni, L.
    Lin, S.
    Tsuji, W.
    ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 : 393 - 394
  • [14] Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis
    Davis, J. C., Jr.
    van der Heijde, D. M.
    Braun, J.
    Dougados, M.
    Clegg, D. O.
    Kivitz, A. J.
    Fleischmann, R. M.
    Inman, R. D.
    Ni, L.
    Lin, S-L
    Tsuji, W. H.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) : 346 - 352
  • [15] Persistent clinical efficacy and safety of anti-tumour necrosis factor a therapy with infliximab in patients with ankylosing spondylitis over 5 years:: evidence for different types of response
    Braun, J.
    Baraliakos, X.
    Listing, J.
    Fritz, C.
    Alten, R.
    Burmester, G.
    Krause, A.
    Schewe, S.
    Schneider, M.
    Soerensen, H.
    Zeidler, H.
    Sieper, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (03) : 340 - 345
  • [16] Long-term efficacy and safety of infliximab treatment of ankylosing spondylitis
    Boeger, CA
    Wittwer, H
    Schattenkirchner, M
    Kellner, M
    JOURNAL OF RHEUMATOLOGY, 2001, 28 : 64 - 64
  • [17] Long-term safety and efficacy of infliximab for the treatment of ankylosing spondylitis
    Elalouf, Ofir
    Elkayam, Ori
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2015, 11 : 1719 - 1726
  • [18] Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept
    Davis, JC
    van der Heijde, DMFM
    Dougados, M
    Braun, J
    Cush, JJ
    Clegg, DO
    Inman, RD
    de Vries, T
    Tsuji, WH
    JOURNAL OF RHEUMATOLOGY, 2005, 32 (09) : 1751 - 1754
  • [19] Persistent clinical response in patients with ankylosing spondylitis after 4 years of treatment with etanercept
    Baraliakos, Xenofon
    Listing, Joachim
    Song, In-Ho
    Haibel, Hildrun
    Rudwaleit, Martin
    Sieper, Joachim
    Braun, Juergen
    SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2008, 37 : 41 - 41
  • [20] Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis
    Sieper, Joachim
    van der Heijde, Desiree
    Dougados, Maxime
    Brown, L. Steve
    Lavie, Frederic
    Pangan, Aileen L.
    ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (05) : 700 - 706
12345